|A tiling resolution DNA microarray with complete coverage of the human genome|
AS Ishkanian, CA Malloff, SK Watson, RJ DeLeeuw, B Chi, BP Coe, ...
Nature genetics 36 (3), 299-303, 2004
|Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study|
E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ...
The lancet oncology 15 (13), 1521-1532, 2014
|Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer|
M Milosevic, P Warde, C Ménard, P Chung, A Toi, A Ishkanian, M McLean, ...
Clinical cancer research 18 (7), 2108-2114, 2012
|Copy number alterations of c‐MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy|
G Zafarana, AS Ishkanian, CA Malloff, JA Locke, J Sykes, J Thoms, ...
Cancer 118 (16), 4053-4062, 2012
|Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies|
R Stoyanova, A Pollack, M Takhar, C Lynne, N Parra, LLC Lam, ...
Oncotarget 7 (33), 53362, 2016
|High‐resolution array CGH identifies novel regions of genomic alteration in intermediate‐risk prostate cancer|
AS Ishkanian, CA Mallof, J Ho, A Meng, M Albert, A Syed, ...
The Prostate 69 (10), 1091-1100, 2009
|Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer|
C Garnis, BP Coe, A Ishkanian, L Zhang, MP Rosin, WL Lam
Genes, Chromosomes and Cancer 39 (1), 93-98, 2004
|NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy|
JA Locke, G Zafarana, AS Ishkanian, M Milosevic, J Thoms, CL Have, ...
Clinical cancer research 18 (1), 308-316, 2012
|Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab|
W Park, D Kwon, D Saravia, A Desai, F Vargas, M El Dinali, J Warsch, ...
Clinical lung cancer 19 (3), 280-288. e4, 2018
|An efficient method for the assessment of DNA quality of archival microdissected specimens|
A Siwoski, A Ishkanian, C Garnis, L Zhang, M Rosin, WL Lam
Modern pathology 15 (8), 889-892, 2002
|Upfront observation versus radiation for adult pilocytic astrocytoma|
A Ishkanian, NJ Laperriere, W Xu, BA Millar, D Payne, W Mason, ...
Cancer 117 (17), 4070-4079, 2011
|Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma|
CM McKee, D Xu, Y Cao, S Kabraji, D Allen, V Kersemans, J Beech, ...
The Journal of clinical investigation 122 (11), 4025-4036, 2012
|TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair|
A Dal Pra, E Lalonde, J Sykes, F Warde, A Ishkanian, A Meng, C Maloff, ...
Clinical Cancer Research 19 (18), 5202-5209, 2013
|Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer|
AS Ishkanian, G Zafarana, J Thoms, RG Bristow
Acta oncologica 49 (7), 888-894, 2010
|NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer|
A Berlin, E Lalonde, J Sykes, G Zafarana, KC Chu, VR Ramnarine, ...
Oncotarget 5 (22), 11081, 2014
|Radiation-induced enhancement of antitumor T-cell immunity by VEGF-targeted 4-1BB costimulation|
B Schrand, B Verma, A Levay, S Patel, I Castro, AP Benaduce, ...
Cancer research 77 (6), 1310-1321, 2017
|Methods for high throughput validation of amplified fragment pools of BAC DNA for constructing high resolution CGH arrays|
SK Watson, RJ DeLeeuw, AS Ishkanian, CA Malloff, WL Lam
BMC genomics 5, 1-8, 2004
|4-1BB aptamer-based immunomodulation enhances the therapeutic index of radiation therapy in murine tumor models|
AP Benaduce, R Brenneman, B Schrand, A Pollack, E Gilboa, A Ishkanian
International Journal of Radiation Oncology* Biology* Physics 96 (2), 458-461, 2016
|Posterior sternoclavicular joint dislocation: case report and discussion|
N Kuzak, A Ishkanian, RB Abu-Laban
Canadian Journal of Emergency Medicine 8 (5), 355-357, 2006
|P1. 07-025 correlating ISEND and tumor mutation burden (TMB) with clinical outcomes of advanced non-small cell lung cancer (ANSCLC) patients on nivolumab|
W Park, G Lopes, D Kwon, V Florou, YK Chae, J Warsch, A Ishkanian, ...
Journal of Thoracic Oncology 12 (11), S2005-S2006, 2017